Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

SILVER SPRING, Md., July 25, 2013 /PRNewswire/ --  

  • Total Revenues of $280.6 million
  • Earnings per Share of $1.60 per Basic Share or $1.52 per Diluted Share
  • Earnings Before Non-Cash Charges of $3.29 per Basic Share, or $3.11 per Diluted Share
  • United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2013.

    "I am very pleased with our second quarter results and the continued strong growth of our core business," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "We continue to assist more patients than ever to manage pulmonary arterial hypertension while we also continue to develop new possibilities for the future, such as the implantable Remodulin pump."

    Total revenues for the quarter ended June 30, 2013 were $280.6 million, up from $225.6 million for the quarter ended June 30, 2012. Net income for the quarter ended June 30, 2013 was $79.9 million or $1.60 per basic share, compared to $72.3 million or $1.37 per basic share for the same quarter in 2012. Gross margin from sales was $245.2 million for the quarter ended June 30, 2013, compared to $192.2 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended June 30, 2013 were $163.7 million, compared to $127.7 million for the same quarter in 2012.(1)

    See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below.Financial Results for the Three Months Ended June 30, 2013 Revenues

    The table below summarizes the components of net revenues (dollars in thousands):Three Months Ended June 30,Percentage Change20132012Cardiopulmonary products:Remodulin

    $

    '/>"/>
    SOURCE United Therapeutics Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
    2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
    3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
    4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
    5. Prevagen® is the Number One Branded Memory Supplement in the United States
    6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
    7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
    8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
    9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
    10. SoundConnect Announces Lync Release in the United States
    11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
    (Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
    (Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ...
    (Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
    Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
    ... Novel system is the first to use rapid, automated DNA ... ... Inc., a leader in the,development of state of the art ... the United States Patent,and Trademark Office (USPTO) recently issued U.S. ...
    ... Expression Genetics, Inc.,(EGEN) announced today that ... selected as one of the Top 10 ... strategic partnering. The selection was made by,an ... leading,provider of business information products and services ...
    ... Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB) (the ... and pharmaceutical raw,materials for use in pharmaceutical, nutraceutical ... announce a Letter of Intent to enter into ... ("Qinba").,Under the proposed terms of this arrangement, Huifeng ...
    Cached Biology Technology:eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 2eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 3Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 2Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 3Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2
    (Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its launch in ... of people to eliminate the pain of trying to remember ... their own biometrics fused to their smartphones. To assist people ... Labs , the company that created 1U and focuses on ...
    (Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
    (Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
    Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
    ... Institute of Marine Science continue to monitor the algal blooms ... few weeks. These "red tides" occur in the lower Bay ... area than in years past, likely due to last winter,s ... by dense blooms of tiny marine plants called algae that ...
    ... , PROVIDENCE, R.I. [Brown University] Policymakers struggling to ... questions on the scale of millions of people and ... the impact of many potential interventions, alone or in ... 2012 International AIDS Society Conference in Washington, D.C., Brandon ...
    ... Ethical Treatment of Animals (PETA) Foundation UK has submitted ... the European Chemicals Agency (ECHA) is failing to fulfil ... which animal testing could be avoided under the rules ... in EU institutions and agencies, and PETA maintains that ...
    Cached Biology News:Researchers monitor 'red tides' in Chesapeake Bay 2Computers can predict effects of HIV policies 2Computers can predict effects of HIV policies 3PETA files complaint with European ombudsman over animal testing for REACH 2
    ... Caspase-9 Pan-Caspase In Situ Assay Kit, Fluorescein ... active caspases in cells undergoing apoptosis. The ... for use in diagnostic or therapeutic procedures. ... use a novel approach to detect active ...
    ... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
    ... as well as other yeasts, has become ... laboratories. The ability to transform whole cells ... DNAs using lithium based buffers and polyethylene ... library screening easy and reliable, especially when ...
    ...
    Biology Products: